Lilly Big Pharma

Quote






It is unfortunate that the amyloid plaque theory for treating Alzheimer's is failing as evidenced by Lilly's clinical trial results reported November 23. However, there is hope an alternative solution.

''While there is no cure, prevention or treatment to slow the progression of Alzheimer's disease, there are five prescription medications approved by the U.S. Food and Drug Administration (FDA) to treat its symptoms.''...... http://www.alz.org/i-have-alz/treatments-and-research.asp. None of the five FDA Alzheimer's approved drugs work to alter the progression of the disease.

On Nov. 22, 2016 of this very same week that Lilly reported its failure, Anavex Life Sciences Corp. (AVXL) announced a positive 41-week update from its Phase 2a study in mild-to-moderate Alzheimer’s disease (AD) patients for ANAVEX 2-73, which targets cellular homeostasis.

Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimer’s Disease - Investigational Treatment suggests to curb Cognitive and Functional Decline.

Read more: http://www.nasdaq.com/press-release...-with-alzheimers-20161122-00252#ixzz4QwSDtLT5

''At 41 weeks, Alzheimer’s patients taking a daily oral dose of ANAVEX 2-73 in the exploratory, not yet dose optimized Phase 2a clinical trial, showed a stabilization of cognitive and functional measures. This data of stabilization is promising since Alzheimer’s disease is a progressive disease where current therapeutics are only able to temporarily slow the worsening of dementia symptoms and not stop the disease from progressing.''

It is interesting too that Anavex and Lilly are scheduled to be present at the 9TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) DECEMBER 8-10, 2016. This may be be an opportunity for a report about an alternative to the plaque amyloid theory that might work.

Alzheimer's is undoubtedly an extremely complicated disease. It is likely that multiple treatments will be the answer. Anavex 2-73 may be one solution to treat this dreaded disease.
 






It is unfortunate that the amyloid plaque theory for treating Alzheimer's is failing as evidenced by Lilly's clinical trial results reported November 23. However, there is hope an alternative solution.

''While there is no cure, prevention or treatment to slow the progression of Alzheimer's disease, there are five prescription medications approved by the U.S. Food and Drug Administration (FDA) to treat its symptoms.''...... http://www.alz.org/i-have-alz/treatments-and-research.asp. None of the five FDA Alzheimer's approved drugs work to alter the progression of the disease.

On Nov. 22, 2016 of this very same week that Lilly reported its failure, Anavex Life Sciences Corp. (AVXL) announced a positive 41-week update from its Phase 2a study in mild-to-moderate Alzheimer’s disease (AD) patients for ANAVEX 2-73, which targets cellular homeostasis.

Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimer’s Disease - Investigational Treatment suggests to curb Cognitive and Functional Decline.

Read more: http://www.nasdaq.com/press-release...-with-alzheimers-20161122-00252#ixzz4QwSDtLT5

''At 41 weeks, Alzheimer’s patients taking a daily oral dose of ANAVEX 2-73 in the exploratory, not yet dose optimized Phase 2a clinical trial, showed a stabilization of cognitive and functional measures. This data of stabilization is promising since Alzheimer’s disease is a progressive disease where current therapeutics are only able to temporarily slow the worsening of dementia symptoms and not stop the disease from progressing.''

It is interesting too that Anavex and Lilly are scheduled to be present at the 9TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) DECEMBER 8-10, 2016. This may be be an opportunity for a report about an alternative to the plaque amyloid theory that might work.

Alzheimer's is undoubtedly an extremely complicated disease. It is likely that multiple treatments will be the answer. Anavex 2-73 may be one solution to treat this dreaded disease.
 






Top Bottom
Back
Quote